Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group.
Sampaio-Barros PD, Pereira IA, Hernández-Cuevas C, Berman A, Burgos-Vargas R, Gutierrez MA, Barcelos A, Chávez-Corrales JE, Moreno M, Palleiro DR, Saénz-Castro R, Stekman I, Azevedo VF, Braga-da-Silva JA, Citera G, Flores-Alvarado D, Gonçalves CR, Graf C, Nitsche A, Saavedra J, Ximenes AC, Vázquez-Mellado J, Collantes-Estevez E; Respondia Group. Sampaio-Barros PD, et al. Among authors: chavez corrales je. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):484-9. Epub 2013 Jul 29. Clin Exp Rheumatol. 2013. PMID: 23899968
Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease.
Pérez Alamino R, Maldonado Cocco JA, Citera G, Arturi P, Vazquez-Mellado J, Sampaio-Barros PD, Flores D, Burgos-Vargas R, Santos H, Chavez-Corrales JE, Palleiro D, Gutierrez MA, Vieira-Sousa E, Pimentel-Santos FM, Paira S, Berman A, Moreno-Alvarez M, Collantes-Estevez E; RESPONDIA Group. Pérez Alamino R, et al. Among authors: chavez corrales je. J Rheumatol. 2011 Aug;38(8):1656-60. doi: 10.3899/jrheum.101049. Epub 2011 Jun 1. J Rheumatol. 2011. PMID: 21632676
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Job Deslandre C, Minden K, Punaro M, Block AJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Lovell DJ, et al. Arthritis Rheumatol. 2015 Oct;67(10):2759-70. doi: 10.1002/art.39234. Arthritis Rheumatol. 2015. PMID: 26097215 Free PMC article. Clinical Trial.
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Ruperto N, et al. Arthritis Rheum. 2010 Jun;62(6):1792-802. doi: 10.1002/art.27431. Arthritis Rheum. 2010. PMID: 20191582 Free article. Clinical Trial.
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Shim SC, Božić-Majstorović L, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Cons Molina FF, Medina-Rodriguez FG, Miranda P, Shesternya P, Chavez-Corrales J, Wiland P, Jeka S, Garmish O, Hrycaj P, Fomina N, Park W, Suh CH, Lee SJ, Lee SY, Bae YJ, Yoo DH. Shim SC, et al. Rheumatology (Oxford). 2019 Dec 1;58(12):2193-2202. doi: 10.1093/rheumatology/kez152. Rheumatology (Oxford). 2019. PMID: 31184752 Free PMC article. Clinical Trial.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Ytterberg SR, et al. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. N Engl J Med. 2022. PMID: 35081280 Clinical Trial.
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
Suh CH, Yoo DH, Berrocal Kasay A, Chalouhi El-Khouri E, Cons Molina FF, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Linde T, Hrycaj P, Abello-Banfi M, Hospodarskyy I, Jaworski J, Piotrowski M, Brzosko M, Krogulec M, Shevchuk S, Calvo A, Andersone D, Park W, Shim SC, Lee SJ, Lee SY. Suh CH, et al. BioDrugs. 2019 Feb;33(1):79-91. doi: 10.1007/s40259-018-00331-4. BioDrugs. 2019. PMID: 30719632 Free PMC article. Clinical Trial.
Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
Soriano ER, Galarza-Maldonado C, Cardiel MH, Pons-Estel BA, Massardo L, Caballero-Uribe CV, Achurra-Castillo AF, Barile-Fabris LA, Chávez-Corrales J, Díaz-Coto JF, Esteva-Spinetti MH, Guibert-Toledano M, Palazuelos FI, Keiserman MW, Lomonte AV, Mota LM, Pineda Villaseñor C, Alarcón GS; GLADAR (Grupo Latino Americano de Estudio de Artritis Reumatoide). Soriano ER, et al. Rheumatology (Oxford). 2008 Jul;47(7):1097-9. doi: 10.1093/rheumatology/ken015a. Epub 2008 May 7. Rheumatology (Oxford). 2008. PMID: 18463144 No abstract available.
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W, Božić-Majstorović L, Milakovic D, Berrocal Kasay A, El-Khouri EC, Irazoque-Palazuelos F, Molina FFC, Shesternya P, Miranda P, Medina-Rodriguez FG, Wiland P, Jeka S, Chavez-Corrales J, Garmish O, Linde T, Rekalov D, Hrycaj P, Krause A, Fomina N, Piura O, Abello-Banfi M, Suh CH, Shim SC, Lee SJ, Lee SY, Kim SH, Yoo DH. Park W, et al. MAbs. 2018 Aug/Sep;10(6):934-943. doi: 10.1080/19420862.2018.1487912. Epub 2018 Jul 16. MAbs. 2018. PMID: 30010481 Free PMC article. Clinical Trial.
Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.
Mezones-Holguin E, Gamboa-Cardenas RV, Sanchez-Felix G, Chávez-Corrales J, Helguero-Santin LM, Laban Seminario LM, Burela-Prado PA, Castro-Reyes MM, Fiestas F. Mezones-Holguin E, et al. Front Pharmacol. 2019 Nov 15;10:1010. doi: 10.3389/fphar.2019.01010. eCollection 2019. Front Pharmacol. 2019. PMID: 31798442 Free PMC article.